Pyk2 Inhibitors
1 drugsAbout Pyk2
Proline-rich tyrosine kinase 2 (Pyk2) is a non-receptor tyrosine kinase in the focal adhesion kinase (FAK) family, sharing structural similarities with FAK but exhibiting distinct expression patterns and activation mechanisms. It plays a role in cell proliferation, migration, and survival, particularly within the tumor microenvironment.
Pyk2's involvement in key cellular processes makes it a potential therapeutic target, especially in oncology. Currently, there is no genetic evidence directly linking Pyk2 to specific diseases, but its functional role suggests therapeutic potential.
Pyk2 is targeted by one FDA-approved small molecule drug, AVMAPKI FAKZYNJA CO-PACK (COPACKAGED), developed by Verastem Inc for oncology indications. This drug was first approved in 2025.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Low Grade Serous Ovarian Cancer with only 1 trials.
- phase2 represents biological uncertainty with 50% completion.
Top Drugs
Verastem Inc. is the only company with an approved drug targeting Pyk2.
The lack of competitors suggests high entry barriers or perceived risk, but also a first-mover advantage.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Pyk2, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
Clinical Trials 42 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 14 | 9 | 0 | 5 | 100% |
| Phase 2 | 15 | 3 | 2 | 10 | 60% |
| Phase 3 | 6 | 4 | 0 | 2 | 100% |
| Phase 4 | 7 | 4 | 1 | 2 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2025 - 2025)
The first and only drug targeting Pyk2 was approved in 2025.
The recent approval suggests renewed interest in Pyk2, but further approvals are needed to validate the target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 32 clinical trials targeting Pyk2.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities